Profectus BioSciences, Inc. In-Licenses Portfolio of Patents to Support Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses
Published: Sep 21, 2011
BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that it has in-licensed a portfolio of patents to support its vaccine program for Ebola and Marburg viruses. Assembled from a number of academic and biopharma sources, the patents provide Profectus with access to the enabling technologies needed to advance its recombinant Vesicular Stomatitis Virus (rVSV) vectored vaccine through commercialization.